WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Researchers uncover future variations of irrigation water use in ChinaOne in 10 Germans becomes victims of identity theft: surveyRailway services resume in east China after 7.3Asian economy forecast to grow 4.5 pct in 2024: reportChina's Qinghai sees significant growth in green coverage in 2023Chang'e 6 to carry foreign science payloadsChina to build pilot zones for special needs education reformChina launches nationwide crackdown on trafficking of women, childrenChina releases ecological protection compensation regulationsXinjiang diverts floodwater to revive forests impacted by drought
2.9138s , 6501.8203125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Insight news portal